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The purpose of this document is to address the current lack of 
consensus regarding the management of hyperbilirubinaemia 
in neonates in South Africa. If left untreated, severe 
neonatal hyperbilirubinaemia may cause kernicterus and 
ultimately death and the severity of neonatal jaundice is 
often underestimated clinically. However, if phototherapy is 
instituted timeously and at the correct intensity an exchange 
transfusion can usually be avoided. The literature describing 
intervention thresholds for phototherapy and exchange 
The range of different thresholds for the initiation of 
phototherapy and exchange transfusion in newborn infants 
in South Africa reflects the same lack of consensus that exists 
worldwide.1 There are also no local evidence-based guidelines 
on how to manage infants who are jaundiced but do not 
require phototherapy, and there is a worrying misconception 
among some medical staff that a single total serum bilirubin 
(TSB) level below the phototherapy threshold is sufficient basis 
to discharge infants with only visual review thereafter. 
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transfusion in both term and preterm infants is therefore 
reviewed and specific intervention thresholds that can be 
used throughout South Africa are proposed and presented 
graphically. A simplified version for use in a primary care 
setting is also presented. All academic heads of neonatology 
departments throughout South Africa were consulted in the 
process of drawing up this document and consensus was 
achieved. 
S Afr Med 1 2006; 96: 819-824. 
A national guideline for the management of neonatal 
jaundice will help facilitate uniform care and admission criteria 
and could ultimately improve the care of jaundiced neonates. 
This document is the result of collaboration with the heads of 
neonatal departments of all South African medical faculties. 
International recommendations for 
the use of phototherapy and exchange 
transfusion in jaundiced term and near-
term infants 
The aim of phototherapy and exchange transfusion is to avoid 
kernicterus. The pathological definition of kernicterus is gross 
yellow staining in the brainstem nuclei with microscopic 
evidence of neuronal damage.2 However, in the literature 
reviewed, kernicterus was defined by any of the following: 
postmortem pathological findings, acute clinical findings 
(bilirubin encephalopathy) and typical chronic neurological 
sequelae. 
In 1952, before the use of phototherapy was established, 
Hsia et af.3 studied 229 infants with erythroblastosis fetalis. 
They demonstrated that when TSB levels exceeded 340 pmol/ 
1, the risk of kernicterus increased significantly and at 
TSB levels above 510 pmol/1 the risk rose to 50%, despite 
exchange transfusion. When they introduced a policy of 
attempting to keep the TSB level below 340 pmol/1 using 
exchange transfusion, there were no cases of kernicterus in 
200 consecutive cases. Twenty years later, Oski and Naiman4 
published a nomogram that was constructed by Diamond and 
Allen, specifically for use with infants with erythroblastosis 
fetalis. Despite the introduction of phototherapy, the TSB level 
above which exchange was obligatory remained at 340 pmol/1 
for both term and preterm infants. 
By 1979 the use of phototherapy was well established. 
Cockington5 used Diamond and Allen's nomogram as a 
basis for recommendations on when to perform exchange 
transfusion and added recommendations on when to initiate 
phototherapy. Despite the availability of phototherapy, he did 
not raise the level of obligatory exchange. However, following 
a recommendation by Karabus,S·6 Cockington devised different 
thresholds according to birth weight and age in hours. He did 
not suggest different thresholds for infants with other risk 
factors. 
Although he did not define the recommended irradiance 
level of the phototherapy it must have been low because he 
used a bank of only 12 white fluorescent bulbs. However, his 
small study of 85 cases across all weight groups showed the 
suggested phototherapy intervention levels to be effective at 
preventing the need for exchange transfusion in most infants. 
Cockington' s charts remain in use in some centres in the UK 
today! and they are recommended in a definitive local text by 
Harrison.7 
Since Cockington, there have been several other 
recommendations, all based on limited evidence.1 A recent, 
comprehensive review8 of the available evidence for the 
management of jaundiced term and near-term (> 34 weeks' 
gestation) infants was published in 2004 by Stanley Ip, and the 
American Academy of Pediatricians' (AAP) Subcommittee on 
Hyperbilirubinemia. 
The report concluded that kernicterus has a 10% mortality 
and 70% morbidity risk versus the risk of permanent 
sequelae caused by exchange transfusion of 5-10%. The 
reviewed studies of infants who already have kernicterus 
showed that the vast majority of term and near-term infants 
with kernicterus and co-morbidity (e.g. sepsis, haemolysis) 
had a peak recorded TSB of > 342 pmol/1. The infants with 
kernicterus who had no associated co-morbidity showed 
a higher peak with a TSB range from 385 to 923 }lmol/1. 
Although acute kernicterus (bilirubin encephalopathy) can 
be completely reversible if treated by exchange transfusion/ 
only 14% of the group reviewed by Ip et al. are known to have 
survived without chronic sequelae. However, much of the data 
were missing, so this number may be higher. 
Contrary to the retrospective review of infants with 
kernicterus, the review of prospective studies of all infants 
with hyperbilirubinaemia showed many infants who did not 
develop kernicterus, with bilirubin levels well over 428 pmol/1. 
There was also no consistent association between peak TSB 
and intelligence quotient, long-term neurological problems or 
permanent hearing loss. However, the data from the largest 
contributing study,10 the Collaborative Perinatal Project (CPP), 
were subsequently shown11 to be significantly confounded by 
the beneficial effect of exchange transfusion that was done in 
53% of infants with TSB > 342 pmol/1 and this would have 
included virtually all infants with peak TSB > 428 pmol/1 
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(phototherapy was not yet widely available at the time of 
data collection, 1959- 1966). Thus, while most infants with 
kernicterus have TSB > 342 pmol/1, most infants with TSB 
> 428 pmol/1 do not have problems if the level of bilirubin is 
reduced rapidly (i.e. via exchange transfusion). 
Ip's review formed the basis of the updated AAP 
recommendations published in 2004.12 These recommendations 
differed from the 1994 AAP recommendations (Table 1)13 in that 
the TSB levels were plotted onto an hour-based curve (Figs 1 
and 2). The availability of high-intensity phototherapy and the 
acknowledgement of specific risk groups, resulted in relatively 
raised phototherapy and exchange transfusion thresholds for 
well term infants and different intervention levels for infants 
at risk. High-intensity phototherapy is recommended as a first-
line intervention, but immediate exchange is recommended if 
TSB levels at presentation are greater than 85 pmol/1 above the 
exchange threshold or if bilirubin levels are not expected below 
the exchange threshold within 6 hours. 
The approach to the jaundiced term and near-term infant has 
been further refined by Bhutani et a/.,14 who derived an hour-
and age-based bilirubin centile chart from a study of 17 854live 
births between 1993 and 1997 (Fig. 3). This chart assigns risk 
of progression to higher levels depending on the current level 
of the TSB. Thus 39.5% of infants with TSBs in the high-risk 
zone after age 18 hours will remain in that zone 24 hours later, 
12.9% of infants in the high-intermediate zone will cross into 
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Fig. 1. Exchange transfusion thresholds recommended by AAP, 200i2 
(reproduced with permission). 
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Fig. 3. Risk designation of term and near-term newborn infants, based on 
their hour-specific bilirubin levels14 (reproduced with permission). 
the high-risk zone and 2.2% of infants in the low-intermediate 
zone will cross into the high-risk zone. None of the infants 
in the low-risk zone will cross into the high-risk zone. This 
information assists discharge planning for infants who are 
jaundiced, but do not require phototherapy. The application of 
this chart according to risk zone is recommended15 as follows: 
(i) high-risk zone - start phototherapy if threshold reached. 
Repeat TSB in 6 - 12 hours; (ii) high-intermediate risk zone 
- repeat TSB within 24 hours; (iii) low-intermediate risk zone 
-repeat TSB within 48 hours; (iv) low-intermediate risk zone 
- clinical evaluation only within 48 hours. 
International recommendations for 
the use of phototherapy and exchange 
transfusion in jaundiced low-birth-
weight and very-low-birth-weight 
infants 
The management of low-birth-weight infants is less clear 
than that of term infants. Cockington's guidelines5 extended 
to infants less than 1 500 g but had no further weight 
subdivisions. In 1985, the National Institute for Child Health 
and Human Development (NICHD) published thresholds16 
for infants who weighed less than 1 250 g, but they did not 
provide a time component (Table II). In 1994, Watchko and 
Table I. AAP 1994: Management of hyperbilirubinaemia in the healthy term newborn13 




Exchange transfusion if 
intensive phototherapy fails 
Exchange transfusion 





Jaundiced infants this age are not considered healthy and require further evaluation 
2170 2260 2340 
2 260 2 310 2 430 




Table II. Varying recommendations for exchange transfusion in preterm infants: Birth weight (g) v. bilirubin (Jlmol/1) 
thresholdsl•,Is,zo-z3 
Ives in Rennie 
Birth weight, g NICHD Ahlfors Maisels in Avery and Roberton NICHHD Trial 
(gestation) 1985 1994 et al. 1999 1999 Cashore 2000 2002 
Risk factor Subtract Subtract 'Use lower Subtract 'Use lower Not specified 
adjustment 40 jlmol/1 40 jlmol/1 values' 40 jlmol/1 values' 
500-749 220 220 220-275 200 204-255 220 
750-999 220 220 220-275 200 255 255 
(< 28wks) 
1000-1249 220 220 220-275 250 255-306 Not specified 
(28- 31 wks) 
1250-1499 255 255 220-275 300 289-340 Not specified 
(32- 34 wks) 
1500-1999 289 290 275-300 350 Not specified Not specified 
(35- 36 wks) 
* wks ::: weeks. 
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rm 
PHOTOTHERAPY 
South African Neonatal Academic Hospital Guidelines: 2006 
In presence of risk factors use one line lower (the gestation below) until <1000g. 
If gestational age is accurate, rather use gestational age (weeks) instead of body weight 
Infants > 12 hours old with TSB level below threshold, repeat TSB level as follows: 
1- 20JJmo/IL below line: repeat TSB in 6hrs or start phototherapy and rept TSB in 12- 24hrs, 
21- 50 jJmoi!L below line: repeat TSB in 12- 24hrs, 
>50 flmOIIL below line: rept TSB until it is falling and/or until jaundice is clinically resolving 
Infants under pf;lototherapy: -
Check the TSB 12- 24 hly but if TSB >30 !Jmolll above the line , check TSB 4 - 6hly. 
STOP phototherapy: 
If TSB >50 flmoi!L below the line. Recheck TSB in 12- 24hr. 
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Start intensive phototherapy when the TSB is it the line accOrding to gestation or weight. 
Fig. 4. Phototherapy guidelines for all gestational ages. 
Claasen17 compared the 1985 NICHD 
criteria with a retrospective review of 
postmortem records and 56% of the 78 
infants who did not have kernicterus 
had bilirubin levels greater than that 
suggested as exchange criteria by the 
NICHD. In 2000, Cashore18 suggested 
elevated thresholds (Table II) and 
extended the weight range as low as to 
500 g. However, a wide range was given 
and no time component provided. 
In 2003, the review by Watchko and 
Maisels19 quotes a wide range of TSB 
levels (170- 306 pmol/1) in preterm 
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infants < 1 500 g with kernicterus. These 
levels are considerably lower than those 
reported in earlier studies of preterm 
infants who generally weighed more 
than 1 500 g. Although co-morbid 
factors such as sepsis, haemolysis and 
hypoxia are thought to be responsible 
for kernicterus at such low levels, the 
only group that have been shown to be 
at increased risk of neurological deficit 
are those with grade 1 intraventricular 
haemorrhage or higher. A review of 
studies that tried to find an association 
between peak TSB and subsequent 
neurological abnormality, failed to show 
a consistent association. Thresholds 
recommended by Maisels}0 Ives}1 
Ahlfors22 and the NICHHD Neonatal 
Network triaF3 show a range of 
interventions with considerable overlap 
(Table II). 
South African 
recommendations for the 
use of phototherapy and 
exchange transfusion in 
hospitals 
When creating charts to guide the use of 
phototherapy and exchange transfusion 
in South African hospitals and primary 
care units, we aimed to provide 
intervention levels that would be based 
on available evidence and would also 
be safe according to available resources. 
We also aimed to provide guidance on 
when phototherapy should be stopped 
and when TSB levels should be repeated 
in jaundiced infants who do not require 
phototherapy. 
The nomogram from Bhutani et 
al.14 shows that term and near-term 
infants enter a high-risk zone at a level 
slightly below the AAP 2004 upper 
phototherapy threshold.12 The AAP 
2004 guidelines suggest the use of 
high-intensity phototherapy from the 
start and also suggest a lower threshold 
for babies who are haemolysing or 
have other risk factors for early-
onset kernicterus. High-intensity 
phototherapy has been defined as that 
which provides an irradiance of at 
least 30 p WI cm2 / nm in the 430 - 490 
nm band. 12 Phototherapy at this level 
resulted in a 45% drop in TSB levels 
in term infants with non-haemolytic 
unconjugated hyperbilirubinaemia, and 
increasing the intensity did not result 
in significantly faster rates of fall of 
bilirubin levels. 24 
However, high-intensity phototherapy 
is not always available and haemolytic 
disease might only be diagnosed after 
laboratory evaluation and/ or response 




South African Neonatal Academic Hospital Guidelines: 2006 
In presence of sepsis, haemolysis, acidosis, or asphyxia, 
use one line lower (gestation below) until <1000g 
If gestational age is accurate, rather use gestational age (weeks) than body weight 
Note: 1. Infants who present with TSB above threshold should have Exchange done if the 
TSB is not expected to be below the threshold after 6 hrs of intensive phototherapy. 
2. Immediate Exchange is recommended if signs of bilirubin encephalopathy and 
usually also if TSB is >85 1JmoVL above threshold at presentation 
3. Exchange if TSB continues to rise >17 !JmoVUhour with intensive phototherapy 
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Fig. 5. Exchange transfusion guidelines for all gestational ages. 
recommendations therefore have a 
lowered threshold for well term infants: 
30 pmol/llower in the first 36 hours 
and 20 pmol/llower thereafter. We 
also recommend that if the TSB level is 
between 1 and 20 pmol/llower than the 
phototherapy threshold then the TSB 
level should be repeated in 6 hours or 
phototherapy should be commenced 
early and the TSB level repeated within 
at least 24 hours. Infants who require 
phototherapy should have the TSB 
checked at least 24-hourly, but if the TSB 
is > 30 pmol/1 above the phototherapy 
threshold then the TSB should be 
checked 4- 6-hourly. 
We have formally adopted the AAP 
thresholds for exchange transfusion 
in term and near-term infants 
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without any alteration. The thresholds 
we recommend for preterm infants are 
based on a combination of guidelines 
(Table II) that were summarised in 
the most recent review by Watchko 
and Maisels, 19 and we have displayed 
the recommendations for exchange 
transfusion for term and preterm infants 
on one chart. 
The final charts for hospital use (Figs 
4 and 5) are displayed graphically. 
Gestational equivalents are provided 
because more mature growth-restricted 
infants can be treated at relatively 
higher thresholds. 
Comparison of the top line of 
phototherapy chart with Bhutani's 
chart shows the following approximate 
relationship after 12 hours' age: (i) 
high-risk zone - starts 20 pmol/llower 
than phototherapy threshold; (ii) high-
intermediate risk zone- 21 -50 pmol/1 
lower than phototherapy threshold; (iii) 
low-intermediate risk zone- starts 51 -
100 pmol/llower than phototherapy 
threshold; (iv) low-intermediate risk 
zone-> 100 pmol/llower than 
phototherapy threshold. 
We therefore suggest that this 
relationship be used to guide timing of 
repeat TSB levels and this is shown on 
the phototherapy chart. 
Simplified phototherapy 
charts for primary care 
The difference in resources and 
experience between primary care 
facilities and hospitals prompted us 
to develop simplified phototherapy 
charts for infants ?: 2 kg and > 35 weeks' 
gestation (Fig. 6). These charts are 
weight-specific and replicate the top 
two lines of the hospital charts, with the 
other intervention thresholds 20 pmol/1 
and 50 pmol/1 below the phototherapy 
threshold drawn in. They also include 
recommendations for referral to higher 
levels of care. 
Recommendations for 
stopping phototherapy 
The AAP recommends that infants 
who are admitted for phototherapy 
continue until the TSB is < 240 pmol/ 
1,12 a level that is 100 pmol/1 below 
the photography threshold for well 
5-day-old infants. They comment 
that discharge need not be delayed to 
observe the infant for rebound of TSB 
levels after phototherapy is stopped, 
but TSB should be rechecked in 24 
hours. This decision is informed by 
three studies25' 27 that applied this cut-
off point. The maximum rebound for 
term and near-term infants when this 
level is adhered to was 60 pmol/J.27 
When low-birth-weight infants were 
studied,26 arbitrary levels of 130 
pmol/1 and 75 pmol/l were chosen 
to stop phototherapy in infants 1 - 1.8 
kg and less than 1 kg, respectively 
··-·---·-·-PliOT'OTHf:i~AJ>y AND T<>T AL sERUM-iiii~iRlJBiN"(~rsB)M<>NIT·c·> .. RII\i'(f~-·~~--·~·-~-· 
IN THE FIRST WEEK OF LIFE AT PRIMARY CARE 
(South At'riean Neonatal Academic Hospitals 2006) 
Retbr!Discuss all jaundiced inlhnts who are: < 2Kg or< 35wks gestation. 
Rclbr all infants of mothers who have Rhesus antibodies on antenatal screening. 
Discuss <1..1,1 infants receiving phototherapy, daily, with MOU doctor (day) or referral hospital (night) 
Stop phototherapy when TSB > 50~mol/L bcl.ow phototherapy line. 
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Fig. 6. Phototherapy guidelines for use in primary care. 
and the maximum rebound was 30 
llmol/1. Based on these data, our safe, 
practical recommendation is to stop 
phototherapy at TSB ;:>: 50 rmol/1 below 
the phototherapy threshold for all 
infants and to check the TSB again in 
12 - 24 hours. 
Final comments 
The consensus guidelines presented 
here provide clear thresholds for the 
initiation of intensive phototherapy 
and exchange transfusion at hospital 
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level, for the timing of repeat TSB levels 
and for the cessation of phototherapy. 
A simplified version has been provided 
for use at primary care centres with the 
aim of streamlining the referral system. 
The comments and review from Professor M J 
Maisels are gratefully acknowledged. 
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